Leukemia & Lymphoma Society
Overview
The Leukemia & Lymphoma Society (LLS) is a voluntary health organization dedicated to curing leukemia, lymphoma, Hodgkin's disease and myeloma, and to improving the quality of life of patients and their families . LLS funds blood cancer research, provides free information and support services, and advocates for blood cancer patients and their families seeking access to quality and affordable care .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Immune-Onc Therapeutics | Jan 2023 | Series B Extension | - |
| Abintus Bio | Aug 2022 | Series B | Co-investor |
| OncoPep, Inc. | Aug 2014 | Series B | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Leukemia & Lymphoma Society based?
Leukemia & Lymphoma Society is headquartered in Rye Brook, New York, United States.
When was Leukemia & Lymphoma Society founded?
Leukemia & Lymphoma Society was founded in 1949.
How many portfolio companies does Leukemia & Lymphoma Society have?
Leukemia & Lymphoma Society has 3 portfolio companies in Caplight's dataset.
What are some companies in Leukemia & Lymphoma Society's portfolio?
Portfolio companies visible on Caplight include Immune-Onc Therapeutics, Abintus Bio, OncoPep, Inc..
What was Leukemia & Lymphoma Society's most recent investment shown here?
Leukemia & Lymphoma Society's most recent investment in this portfolio sample was in Immune-Onc Therapeutics in 2023.
What sectors does Leukemia & Lymphoma Society focus on?
Leukemia & Lymphoma Society focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Leukemia & Lymphoma Society focus on?
Leukemia & Lymphoma Society typically invests at the Mid stage.
What is Leukemia & Lymphoma Society's AUM?
Leukemia & Lymphoma Society's assets under management are estimated between $500.0M and $1.0B.